Healthy
Conditions
Keywords
volunteer
Brief summary
The purpose of this study is to evaluate safety and tolerability after a single administration of PF-03382792 in healthy volunteers.; and to evaluate plasma drug levels and biological activity.
Detailed description
Evaluate the safety, tolerability, plasma concentrations of PF-03382792 and other biological activity following a single dose of PF-03382792. Three ascending single doses of PF-03382792 were administered in this study (0.05 mg, 0.15mg and 0.5 mg). The decision to terminate the study was made on June 4, 2010 due to safety findings and limitations regarding the levels of the metabolite projected for doses above 0.5 mg.
Interventions
DRUGPF-03382792 Cohort 1
First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
DRUGPF-03382792 Cohort 2
Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
DRUGPF-03382792
Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
DRUGCSF cohort
Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* For all cohorts, healthy male and/or female subjects of nonchildbearing potential between the ages of 18 and 55 years, inclusive.
Exclusion criteria
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. * History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening. * Signs or symptoms of adrenal insufficiency. * Ocular lens (eye) abnormalities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety endpoints include evaluation: adverse events, change from baseline in vital signs, triplicate ECG (Part A only), singlet ECG for Parts B and C. 8 hours of cardiac telemetry postdose (Part A only). | For cohorts in Part A, up to 24 days; for Cohorts in Part B, up to 17; for Part C, up to 10 days |
| Additional Safety endpoints: clinical safety laboratory endpoints, plasma cortisol and ACTH, clinical examinations, slit lamp examination. | For cohorts in Part A, up to 24 days; for Cohorts in Part B, up to 17; for Part C, up to 10 days |
| Pharmacokinetic endpoints: plasma concentration of PF 03382792 over time (eg, AUC, Cmax, Tmax, t1/2), plasma concentration of PF 03227077 over time (eg, AUC, Cmax, Tmax, t1/2). | up to 72 hours post the final dose for each cohort |
Secondary
| Measure | Time frame |
|---|---|
| Plasma aldosterone concentrations. | For Part A and C; up to 24 hours post final dose |
| Change and percent change from baseline in average CSF sAPP fragment concentrations over all postdose collection time points up to 8 hours. • CSF sAPP fragment concentrations over time. • CSF concentration of PF 03382792 and PF | Part C only, up to 8 hours post dose |
| 03227077 over time (eg, AUC, Cmax, Tmax). | Part C only, up to 8 hours post dose |
Countries
United States
Outcome results
None listed